Financial reports
10-Q
2023 Q2
Quarterly report
13 Mar 23
10-Q
2023 Q1
Quarterly report
15 Dec 22
10-K
2022 FY
Annual report
31 Oct 22
10-Q
2022 Q3
Quarterly report
14 Jun 22
10-Q
2022 Q2
Quarterly report
15 Mar 22
10-Q
2022 Q1
Quarterly report
15 Dec 21
10-K
2021 FY
Annual report
29 Oct 21
10-Q
2021 Q3
Quarterly report
11 Jun 21
10-Q
2021 Q2
Quarterly report
15 Mar 21
10-Q
2021 Q1
Quarterly report
11 Dec 20
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Jun 23
8-K
Bankruptcy or Receivership
14 Jun 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Jun 23
8-K
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
18 May 23
8-K
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
16 May 23
8-K
Other Events
27 Apr 23
8-K
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
11 Apr 23
8-K
Other Events
3 Apr 23
8-K
Other Events
22 Feb 23
Registration and prospectus
25-NSE
Exchange delisting
10 Jul 23
D
Indefinite amount in options / securities to be acquired, 7 investors
26 May 23
424B5
Prospectus supplement for primary offering
18 May 23
D
Indefinite amount in options / securities to be acquired, 7 investors
24 Apr 23
424B5
Prospectus supplement for primary offering
11 Apr 23
RW
Registration withdrawal request
10 Apr 23
S-1/A
IPO registration (amended)
3 Apr 23
S-1
IPO registration
27 Mar 23
RW
Registration withdrawal request
28 Feb 23
S-1
IPO registration
1 Feb 23
Proxies
DEF 14A
Definitive proxy
12 Dec 22
PRE 14A
Preliminary proxy
2 Dec 22
DEFA14A
Additional proxy soliciting materials
31 May 22
DEF 14A
Definitive proxy
31 May 22
DEF 14A
Definitive proxy
18 Mar 21
DEFA14A
Additional proxy soliciting materials
18 Mar 21
DEF 14A
Definitive proxy
30 Apr 20
PRE 14A
Preliminary proxy
20 Apr 20
DEFA14A
Additional proxy soliciting materials
7 Feb 20
DEFA14A
Additional proxy soliciting materials
7 Feb 20
Other
UPLOAD
Letter from SEC
10 Feb 23
CORRESP
Correspondence with SEC
1 Feb 23
UPLOAD
Letter from SEC
27 Jan 23
EFFECT
Notice of effectiveness
1 Dec 22
CORRESP
Correspondence with SEC
29 Nov 22
CORRESP
Correspondence with SEC
28 Nov 22
CORRESP
Correspondence with SEC
28 Nov 22
CORRESP
Correspondence with SEC
23 Nov 22
CORRESP
Correspondence with SEC
14 Nov 22
UPLOAD
Letter from SEC
8 Nov 22
Ownership
SC 13G/A
SZOP MULTISTRAT LP
13 Feb 24
SC 13G
INTRACOASTAL CAPITAL, LLC
25 May 23
SC 13G
SZOP Multistrat Management LLC
19 May 23
SC 13G
Lind Global Fund II LP
17 Apr 23
SC 13G/A
Avidity Partners Management LP
14 Feb 23
4
Robert J DelAversano
9 Feb 23
4
Robert J DelAversano
4 Nov 22
4
Spahr Stephany Foster
12 Oct 22
3
Spahr Stephany Foster
12 Oct 22
4
Robert J DelAversano
5 Aug 22